Natural Killer Cell Mediated Immunity
Conditions
Brief summary
Patients undergoing haploidentical allo-HSCT will be prospectively enrolled exploring the NK cells phenotype and functional reconstitution.
Detailed description
Patients with hematological malignancies suitable for allo-HSCT but without HLA-identical related or unrelated donors were candidates for the HLA-haploidentical HSCT. Patients undergoing haploidentical allo-HSCT will be prospectively enrolled exploring the NK cells phenotype and functional reconstitution. Peripheral blood will be collected by day15, 30, 60, 90, 180, and 1 year post transplantation.
Interventions
DRUGMMF
MMF withdrawal by engraftment post haplo-SCT
Sponsors
Peking University People's Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* AML or MDS or CML or ALL undergoing haploidentical stem cells transplantation
Exclusion criteria
* NR or refractory AML/ALL before transplantation donors from mother or collateral related
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immune Reconstitution differences between two group | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative incidence of acute GVHD differences between two group | 100 day |
| Cumulative incidence of chronic GVHD differences between two group | 1 year |
| Cumulative incidence of TRM differences between two group | 1 year |
| Cumulative incidence of Infection differences between two group | 1 year |
| DFS differences between two group | 1 year |
| OS differences between two group | 1 year |
| Cumulative incidence of relapse differences between two group | 1 year |
Countries
China
Contacts
Primary ContactXiangyu Zhao, M.D., PhD
Outcome results
None listed